Perimetrics, Inc. has received clearance from the US Food and Drug Administration (FDA) for the InnerView® System, the first technology authorized to measure both internal and external mobility in teeth and dental implants.
The InnerView System utilizes proprietary Quantitative Percussion Diagnostics (QPD™) technology to assess internal mobility—a mechanical response often associated with early structural changes such as cracks, loose restorations, or other precursors to failure.
"Until now, clinicians have relied on subjective feel or surface observation in their attempts to evaluate cracks or failing restorations," said Robert Hayman, CEO and Chairman of Perimetrics, Inc. "This clearance represents a defining moment for dentistry. Measuring 'internal' mobility—often linked to cracks and loose restorations—gives clinicians new, objective insight into changes that may precede failure."
The InnerView platform builds on more than 10 years of research, including 30 clinical studies and 78 international patents. It is the first FDA-cleared system capable of providing quantitative assessment of internal mobility in natural teeth.
Dental professionals interested in the scientific or clinical background of the technology can learn more at www.innerview.ai or by contacting Perimetrics at info@innerviewai.com.
